Novartis to Acquire Avidity Biosciences
Novartis will acquire Avidity Biosciences for $12 billion, expanding its genetic medicine pipeline.
The all-cash deal gives Novartis ownership of Avidity's RNA-based platform and three programmes targeting neuromuscular disorders, including:
- Duchenne muscular dystrophy
- Myotonic dystrophy type 1
- Facioscapulohumeral muscular dystrophy
Avidity’s innovative platform enables precise delivery of RNA therapeutics to muscle tissue.
The purchase underscores Novartis's strategy to expand into rare and genetic diseases amidst increasing competition.
Author's summary: Novartis acquires Avidity Biosciences for $12 billion to boost genetic medicine pipeline.
More News
- Importing beef is not the solution | GABEL
- Cameco, Brookfield involved in $80 billion U.S. nuclear reactor deal
- You can’t rebrand genocide - The Poly Post
- In Review: Big-Ass Sword by Andreas Butzbach
- ‘AI drives modern innovations’ - Star of Mysore
- Banging bumper fun from 2000AD!
- SKIMS’ chilling vision of the perfect female body
- Brookfield/Cameco-owned Westinghouse secures US nuclear construction deal
- VSee Awarded US Department of Health & Human Services FedRAMP High ATO
- Goodbye to life—Scientists confirm that Earth's oxygen will disappear much sooner than we thought